Vulvar Cancer

One potential target for the ADC Enfortumab Vedotin (EV) is Nectin-4...Nectin-4 could be a potential target in the therapy of women with VSCC. Further (pre-)clinical data is needed to evaluate the use of EV in therapy of women with VSCC.

Transcriptomic profiling explored CXCL8-activated pathways, including cytokine-cytokine receptor interaction, transforming growth factor (TGF)-β signaling pathway, and tryptophan metabolism. These findings highlight CXCL8 as a potential prognostic biomarker for VSCC and underscore its role in driving tumor proliferation, providing a rationale for targeting CXCL8 in vulvar cancer therapy.

P2, N=68, Recruiting, University of Utah | Trial primary completion date: Feb 2026 --> Jun 2026

P=N/A, N=60, Completed, Northwestern University | Trial completion date: Dec 2028 --> Mar 2026 | Trial primary completion date: Dec 2027 --> Dec 2025 | Recruiting --> Completed

P2, N=24, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2025 --> Apr 2026

P1, N=144, Recruiting, Avacta Life Sciences Ltd | Not yet recruiting --> Recruiting

SOX10 and PRAME are nuclear staining markers that can be used for diagnostic purposes and as adjunct markers for the diagnosis of VM and benign melanocytic lesions. PRAME immunostaining shows high specificity for melanoma and melanoma in situ.

P=N/A, N=22, Suspended, Wake Forest University Health Sciences | Recruiting --> Suspended

Further treatment consisted of adjuvant radiotherapy (61 Gy) and doxorubicin-based chemotherapy...Management involves radical surgical resection with adjuvant radiotherapy and chemotherapy as indicated. Reporting such cases is essential to enhance understanding and guide evidence-based management of these challenging neoplasms.

P1, N=144, Not yet recruiting, Avacta Life Sciences Ltd

P2, N=13, Recruiting, Institute of Oncology Ljubljana

ITZ treatment was associated with increased infiltration of M1-like TAMs in cancer tissues, suggesting an immunomodulatory effect. These findings support further investigation of ITZ as a potential adjunct in cancer therapy.